A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice (scientific article published on 28 July 2015)

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function

Q30233581

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

Q30350744

IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection

Q30361079

MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

Q30377215

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

Q30413695

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection

Q33834576

Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice

Q33844931

Immunity to influenza in the elderly

Q33846375

Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity

Q33908690

Rescue of influenza B virus from eight plasmids.

Q34038553

Review of intranasal influenza vaccine

Q34343302

Amplification, expression, and packaging of foreign gene by influenza virus

Q34476695

Antibody-cytokine fusion proteins: innovative weapons in the war against cancer

Q36021080

Effective influenza vaccines for children: a critical unmet medical need and a public health priority

Q36184408

Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria

Q36343961

Influenza vaccination in HIV-infected individuals: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness and safety

Q38240718

Characterization of recombinant influenza A virus as a vector expressing respiratory syncytial virus fusion protein epitopes

Q38986297

Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector

Q39063806

Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts

Q39320513

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

Q39861118

Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice

Q39895816

Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

Q40246250

Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment

Q40391888

Regulatory anatomy of the murine interleukin-2 gene

Q40519016

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

Q40724719

Efficient expression of the tumor-associated antigen MAGE-3 in human dendritic cells, using an avian influenza virus vector.

Q40841536

Membrane-anchored incorporation of a foreign protein in recombinant influenza virions

Q41027411

Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency.